新辅助化疗 肿瘤细胞减灭术治疗晚期卵巢癌的临床意义  

作　　者：成莉[1] 邢辉[1] 

机构地区：[1]湖北文理学院附属襄阳市中心医院,441021

出　　处：《浙江临床医学》2013年第9期1284-1286,共3页Zhejiang Clinical Medical Journal

基　　金：湖北省卫生厅青年科技人才基金项目（QJX2008-61）

摘　　要：目的探讨新辅助化疗结合中间性肿瘤细胞减灭术治疗晚期卵巢癌的临床意义。方法回顾性分析40例晚期卵巢癌患者，按照新辅助化疗后再减瘤和直接手术减瘤分为两组，比较化疗疗效和预后。结果新辅助化疗组化疗有效率88．9％，新辅助化疗组平均术中出血量明显少于直接手术组（P〈0．05）；新辅助化疗组手术时间较直接手术组缩短，两组比较有显著性差异（P〈0．05）。新辅助化疗组满意减瘤率为83．3％，明显高于直接手术组45．5％（P〈0．05）。新辅助化疗组和直接手术组中位生存时间分别为35个月和28个月，差异无统计学意义（P〉0．05）。结论新辅助化疗结合中间性肿瘤细胞减灭术可以明显提高晚期卵巢癌患者手术满意率，但并未延长患者生存期。Objective To study the clinical significance of neoadjuvant chemotherapy combining with interval cytoreductive surgery for advanced ovarian cancer.Methods 40 patients with advanced ovarian cancer were analyzed retrospectively, and were divided into two groups according to whether they had received neoadjuvant chemotherapy or not before operation, the effect of chemotherapy and prognostic factors were analyzed. Results The response rate of chemotherapy was88.9%;The amount of bleeding and time of operation in neoadjuvant chemotherapy group was significantly less than those of without neoadjuvant chemotherapy group;The optimal cytoreductive surgery rate in neoadjuvant chemotherapy group was 83.3%,which was significantly higher than that of without neoadjuvant chemotherapy group（45.5%）;The median survival time of NACT group （35months） was longer than that of control group （28months）;there were no statistically significant differences between two groups in survival rate.Conclusions Neoadjuvant chemotherapy combining with interval cytoreductive surgery for advanced ovarian cancer can obviously improve the operation rate of satisfaction, but does not prolong survival period

关 键 词：新辅助化疗 晚期卵巢癌 中间性肿瘤细胞减灭术 

分 类 号：R737.31[医药卫生—肿瘤]